Skip to main
DGX

Quest Diagnostics (DGX) Stock Forecast & Price Target

Quest Diagnostics (DGX) Analyst Ratings

Based on 11 analyst ratings
Hold
Strong Buy 9%
Buy 27%
Hold 64%
Sell 0%
Strong Sell 0%

Bulls say

Quest Diagnostics is well positioned in the healthcare industry, with strong core trends, outpacing revenue, adjusted EPS and AOI estimates, and increased volumes through recent partnerships. The company's clinical labs and diagnostic testing services remain a critical component in the treatment decision process, and its expansion into new markets and partnerships with organizations like FMS and Corewell show potential for continued growth. However, the company's premium valuation and potential risks such as decelerating volumes and increasing reimbursement headwinds suggest a balanced risk/reward profile, and we maintain a Hold rating.

Bears say

Quest Diagnostics is facing strong competition and may struggle with growing its revenue in the future. Although the company has potential growth opportunities in its Co-Lab and Corewell segments, they have yet to fully materialize and may not meet revenue targets as expected. Additionally, the company's focus on automation and AI may lead to further cost savings, but it remains to be seen if these initiatives will have a significant impact on overall revenue.

Quest Diagnostics (DGX) has been analyzed by 11 analysts, with a consensus rating of Hold. 9% of analysts recommend a Strong Buy, 27% recommend Buy, 64% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Quest Diagnostics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Quest Diagnostics (DGX) Forecast

Analysts have given Quest Diagnostics (DGX) a Hold based on their latest research and market trends.

According to 11 analysts, Quest Diagnostics (DGX) has a Hold consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $215.64, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $215.64, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Quest Diagnostics (DGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.